

# Brands with Generic Equivalents

**Non-Clinical Policy No. 0001**

**Effective Date: 4/1/2019**

**Notes:**

- For non-preferred agents in this class/category, patients must have had an inadequate response to at least TWO\* preferred agents, have a documented intolerance due to severe adverse reaction or contraindication.  
\*If there is only one preferred agent in the class/category documentation of inadequate response to ONE preferred agent is needed
- If a new-to-market drug falls into an existing class/category, the drug will be considered non-preferred and subject to this class/category prior authorization (PA) criteria

**Background:**

This is a general pharmacy program policy applicable to brand name products with a generic equivalent available.

**Policy:**

Criteria	
Initial Authorization	<p>In addition to any drug class or drug specific policy criteria.</p> <p>All criteria must be met in order to approve.</p> <ol style="list-style-type: none"> <li>1. Trial of two* preferred products, other than the generic equivalent to the requested brand; and</li> <li>2. Trial of the generic equivalent of the product being requested from 5 manufacturers. If fewer than 5 manufacturers, must try all manufacturers.</li> </ol> <p>Documentation should include length of trial and outcome. Exceptions to this policy should be made for unique circumstances supported by clinical judgement and documentation.</p> <p>If no additional criteria, <b>Approve for 6 months.</b></p>
Reauthorization	<p>In addition to any drug class or drug specific policy criteria. Documentation of positive clinical response to treatment.</p> <p>If no additional criteria, <b>Approve for 12 months.</b></p>

**History**

Date	Action and Summary of Changes
03/22/2019	New Policy